- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02965287
Validation of a Test for Fetal Malformations
Blind Validation of a Metabolomics Based Test for the Non-invasive Screening of Fetal Malformations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Salerno
-
Montecorvino Pugliano, Salerno, Italy, 84090
- Theoreo srl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria were the ones designed by SCOPE Study:
- Nulliparous women, with a singleton pregnancy, between 14wks, 0 days and 16wks, 6 days gestation who give informed consent to participate in SCOPE.
Exclusion criteria were the ones designed by SCOPE Study:
- Unsure of last menstrual period (LMP)
- Unwilling to have ultrasound scan at ≤20 weeks
- ≥3 miscarriages
- ≥3 terminations
- Essential hypertension treated pre-pregnancy
- Moderate-severe hypertension at booking ≥160/100 mmHg
- Diabetes
- Renal disease
- Systemic lupus erythematosus
- Anti-phospholipid syndrome
- Sickle cell disease
- HIV positive
- Major uterine anomaly
- Cervical suture
- Knife cone biopsy
- Ruptured membranes now
- Long term steroids
- Treatment low-dose aspirin
- Treatment calcium (>1g/24h)
- Treatment eicosapentanoic acid (fish oil)
- Treatment vitamin C ≥1000 mg & Vit E ≥400 iu
- Treatment heparin/low molecular weight heparin
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
19-21 weeks' gestation
The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study. All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose. |
The serum samples will be used to get a metabolomic profile
|
14-16 weeks' gestation
Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients.
The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
|
The serum samples will be used to get a metabolomic profile
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic test performance evaluation in dichotomic classification at 19-21 weeks' gestation
Time Frame: 6 months
|
Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of a malformed fetus through the analysis of a serum sample from a mother at 19-21 weeks' gestation
|
6 months
|
Diagnostic test performance evaluation in the individuation of the exact diagnosis of fetal malformation at 19-21 weeks' gestation
Time Frame: 6 months
|
Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of the type of malformation through the analysis of a serum sample from a mother at 19-21 weeks' gestation
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic test performance evaluation in dichotomic classification at 14-16 weeks gestation
Time Frame: 6 months
|
Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of a malformed fetus through the analysis of a serum sample from a mother at 19-21 weeks' gestation
|
6 months
|
Diagnostic test performance evaluation in the individuation of the exact diagnosis of fetal malformation at 14-16 weeks gestation
Time Frame: 6 months
|
Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of the type of malformation through the analysis of a serum sample from a mother at 14-16 weeks gestation
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jacopo Troisi, Dr., CEO
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MV-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fetal Anomaly
-
University of California, San DiegoWithdrawnMajor Fetal AnomalyUnited States
-
Sohag UniversityNot yet recruiting
-
Samuel Lunenfeld Research Institute, Mount Sinai...WithdrawnPsychological Sequelae of Termination of Pregnancy for Fetal AnomalyCanada
-
Sheba Medical CenterUnknown
-
Assiut UniversityMiddle-East Obstetrics and Gynecology Graduate Education (MOGGE) FoundationNot yet recruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...Azienda Ospedaliero-Universitaria di Parma; Ministero della Salute, Italy; Ospedale...RecruitingBrain Malformation | Fetal AnomalyItaly
-
Beni-Suef UniversityCompleted
-
Mahidol UniversityUnknownFirst Trimester PregnancyThailand
-
China Medical University HospitalUnknownTermination of Pregnancy
Clinical Trials on Serum metabolomics profiling
-
University of SalernoTheoreo SrlCompleted
-
Peking Union Medical College HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory FailureChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThird Affiliated Hospital, Sun Yat-Sen University; The Seventh Affiliated Hospital...Not yet recruiting
-
Peking Union Medical College HospitalGeneCast Biotechnology Co., Ltd.; Geneplus-Beijing Co. Ltd.; OrigiMed; YuceBio...RecruitingHepatocellular Carcinoma | Cholangiocarcinoma | Precancerous Condition | Liver Cancer | Biliary Tract Cancer | Gallbladder Cancer | Healthy, no Evidence of Disease | Benign Hepatobiliary DiseaseChina
-
University of LiegeRecruitingCritical Care | Carnitine Metabolism DisturbancesBelgium
-
Memorial Sloan Kettering Cancer CenterNYU Langone Health; National Institutes of Health (NIH); Weill Medical College... and other collaboratorsCompletedProstate Cancer | Elevated Prostate Specific Antigen (PSA)United States
-
Karolinska University HospitalNot yet recruitingCritical Illness | Hypophosphatemia | Refeeding SyndromeSweden, Czechia, Italy
-
Medical University InnsbruckBiocrates Life Sciences AG, Innsbruck, Austria; Tiroler WissenschaftsförderungCompletedCongenital Heart Disease | Metabolism Disorder
-
Liverpool University Hospitals NHS Foundation TrustRecruiting
-
University of CalgaryUniversity of LethbridgeCompletedConcussion, Mild | Diagnoses, Syndromes, and ConditionsCanada